IGI Logo

Lupin is currently trading at Rs. 738.00, up by 4.95 points or 0.68% from its previous closing of Rs. 733.05 on the BSE.

The scrip opened at Rs. 730.00 and has touched a high and low of Rs. 739.70 and Rs. 730.00 respectively. So far 3014 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 971.30 on 13-Jan-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 744.20 and Rs. 723.00 respectively. The current market cap of the company is Rs. 33513.58 crore.

The promoters holding in the company stood at 47.11% while Institutions and Non-Institutions held 41.44% and 11.45% respectively.

Lupin has launched novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone for managing inadequately controlled asthma amongst patients. The company has launched this important product under the brand name DIFIZMA in India.

Lupin is the first company in India to offer this novel FDC dry powder inhalation (DPI) product combining Indacaterol, a long-acting beta-agonist, Glycopyrronium, a long-acting muscarinic receptor antagonist, and Mometasone Furoate, an inhaled corticosteroid.

DIFIZMA is the only FDC that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled Asthma. DIFIZMA will help in the management of inadequately controlled asthma by improving lung function, providing better symptom control and reducing exacerbations. The drug will be available in one strength with a fixed-dose to be taken once daily.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.